Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
|Headquarters||345 Park Avenue|
NEW YORK, NY, United States 10154
|Chief Executive Officer, Director||Lamberto Andreotti|
|Chief Financial Officer, Executive Vice President||Charles Bancroft|
|President, U.S. Pharmaceuticals||Giovanni Caforio|
|President - Global Manufacturing and Supply||Louis Schmukler|
|Executive Vice President, Chief Scientific Officer, President - Research and Development, Director||Elliott Sigal|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||1.6B||Book Value||$8.36|
|Annual Dividend Rate||$1.40||Price/Sales (TTM)||4.7|
|Ex-Div Date||4/3/13||P/Cash Flow (TTM)||27.5x|
|Pay Date||7/3/13||Operating Margin||6.09%|
*GAAP = prior to non-GAAP analyst adjusted earnings.